

# Cancer cells are the most important target of chemotherapy

Mr. Daniel Davis, Thomas Howard, Kathleen Callahan,  
Kevin Mueller, Michele Johnston, William Barnes,  
Andrew Walker, William Torres, Kevin Black, Lisa Todd,  
Christian Owens

Chung Shan Medical University

**Conclusions** The mechanisms of action of LPS may be related to the different roles of LPS in induced ischemia, hypoxia, and tumorigenesis. **Acknowledgments** The authors thank the S. et al. (2007) authors for their helpful discussions on the effect of lysosomesin 1 and RpM1 antagonists on chemokinesis and tumorigenesis in cancer. The authors also thank the S. et al. (2007) authors for their helpful discussions on the effects of lysosomesin 1 and RpM1 antagonists on chemokinesis and tumorigenesis. **Author Contributions** Conceived and designed the experiments: DADK JM. Performed the experiments: DADK JM. Analyzed the data: DADK JM. Contributed reagents/materials/analysis tools: DADK JM. Wrote the paper: DADK JM. Copyright © 2007 Elsevier Inc. All rights reserved. Copyright © 2007 Elsevier Inc. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2007 Elsevier Inc. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Clinical Cancer 2000; 10(2): 49–59. Journal of Clinical Cancer 2000; 10(2): 49–59. Journal of Clinical Cancer 2000; 10(2): 49–59. Journal of Clinical Cancer 2000; 10(2): 39–69. Journal of Clinical Cancer 2000; 10(2): 69–81. Journal of Clinical Cancer 2000; 10(2): 81–95. Journal of Clinical Cancer 2000; 10(2): 95–105. Journal of Clinical Cancer 2000; 10(2): 105–111. Journal of Clinical Cancer 2000; 10(2): 111–127. Journal of Clinical Cancer 2000; 10(2): 127–138. Journal of Clinical Cancer 2000; 10(2): 138–143. Journal of Clinical Cancer 2000; 10(2): 143–155. Journal of Clinical Cancer 2000; 10(2): 155–176. Journal of Clinical Cancer 2000; 10(2): 176–198. Journal of Clinical Cancer 2000; 10(2): 198–201. Journal of Clinical Cancer 2000; 10(2): 201–209. Journal of Clinical Cancer 2000; 10(2): 209–219. Journal of Clinical Cancer 2000; 10(2): 219–231. Journal of Clinical Cancer 2000; 10(2): 231–237. Journal of Clinical Cancer 2000; 10(2): 237–244. Journal of Clinical Cancer 2000; 10(2): 244–252. Journal of Clinical Cancer 2000; 10(2): 253–257. Journal of Clinical Cancer 2000; 10(2): 258–264. Journal of Clinical Cancer 2000; 10(2): 264–271. Journal of Clinical Cancer 2000; 10(2): 271–279. Journal of Clinical Cancer 2000; 10(2): 279–283. Journal of Clinical Cancer 2000; 10(2): 283–286. Journal of Clinical Cancer 2000; 10(2): 286–293. Journal of Clinical Cancer 2000; 10(2): 293–295. Journal of Clinical Cancer 2000; 10(2): 296–307. Journal of Clinical Cancer 2000; 10(2): 307–310. Journal of Clinical Cancer 2000; 10(2): 310–320. Journal of Clinical Cancer 2000; 10(2): 320–323. Journal of Clinical Cancer 2000; 10(2): 323–327. Journal of Clinical Cancer 2000; 10(2): 327–340. Journal of Clinical Cancer 2000; 10(2): 340–343. Journal of Clinical Cancer 2000; 10(2): 343–348. Journal of Clinical Cancer 2000; 10(2): 348–